Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Clin Epigenetics. 2021 Apr 12;13(1):78. doi: 10.1186/s13148-021-01054-0.
Prenatal symptoms of depression (PND) and anxiety affect up to every third pregnancy. Children of mothers with mental health problems are at higher risk of developmental problems, possibly through epigenetic mechanisms together with other factors such as genetic and environmental. We investigated DNA methylation in cord blood in relation to PND, taking into consideration a history of depression, co-morbidity with anxiety and selective serotonin reuptake inhibitors (SSRI) use, and stratified by sex of the child. Mothers (N = 373) prospectively filled out web-based questionnaires regarding mood symptoms and SSRI use throughout pregnancy. Cord blood was collected at birth and DNA methylation was measured using Illumina MethylationEPIC array at 850 000 CpG sites throughout the genome. Differentially methylated regions were identified using Kruskal-Wallis test, and Benjamini-Hochberg adjusted p-values < 0.05 were considered significant.
No differential DNA methylation was associated with PND alone; however, differential DNA methylation was observed in children exposed to comorbid PND with anxiety symptoms compared with healthy controls in ABCF1 (log twofold change - 0.2), but not after stratification by sex of the child. DNA methylation in children exposed to PND without SSRI treatment and healthy controls both differed in comparison with SSRI exposed children at several sites and regions, among which hypomethylation was observed in CpGs in the promoter region of CRBN (log2 fold change - 0.57), involved in brain development, and hypermethylation in MDFIC (log2 fold change 0.45), associated with the glucocorticoid stress response.
Although it is not possible to assess if these methylation differences are due to SSRI treatment itself or to more severe depression, our findings add on to existing knowledge that there might be different biological consequences for the child depending on whether maternal PND was treated with SSRIs or not.
孕期抑郁(PND)和焦虑的前期症状影响了每三位孕妇中的一位。有精神健康问题的母亲所生的孩子,其发育问题的风险更高,这可能是通过表观遗传机制以及其他因素,如遗传和环境因素共同作用的结果。我们研究了脐带血中的 DNA 甲基化与 PND 的关系,同时考虑了抑郁史、焦虑共病和选择性 5-羟色胺再摄取抑制剂(SSRIs)的使用情况,并按孩子的性别进行了分层。母亲(N=373)前瞻性地填写了在线问卷,内容涉及孕期的情绪症状和 SSRIs 的使用情况。孩子出生时采集脐带血,使用 Illumina MethylationEPIC 芯片在整个基因组的 850000 个 CpG 位点上测量 DNA 甲基化。采用 Kruskal-Wallis 检验识别差异甲基化区域,Benjamini-Hochberg 校正的 p 值<0.05 被认为具有统计学意义。
单独的 PND 与 DNA 甲基化无差异相关;然而,与健康对照组相比,患有 PND 伴焦虑症状的儿童存在 ABCF1 中差异的 DNA 甲基化(log 两倍变化-0.2),但按孩子的性别分层后则不然。与未接受 SSRI 治疗的 PND 暴露儿童和健康对照组相比,接受 PND 暴露且未接受 SSRI 治疗的儿童在几个位点和区域的 DNA 甲基化存在差异,其中在参与大脑发育的 CRBN 启动子区域的 CpG 观察到低甲基化(log2 倍数变化-0.57),而在与糖皮质激素应激反应相关的 MDFIC 中观察到高甲基化(log2 倍数变化 0.45)。
虽然无法确定这些甲基化差异是由于 SSRI 治疗本身还是由于更严重的抑郁,但我们的研究结果增加了现有知识,即根据母亲的 PND 是否用 SSRIs 治疗,孩子可能会有不同的生物学后果。